Compare CME & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CME | SNY |
|---|---|---|
| Founded | 1898 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9B | 116.8B |
| IPO Year | 2002 | N/A |
| Metric | CME | SNY |
|---|---|---|
| Price | $311.43 | $43.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $295.62 | $61.50 |
| AVG Volume (30 Days) | 2.2M | ★ 4.2M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | 3.65% | ★ 3.66% |
| EPS Growth | ★ 15.41 | N/A |
| EPS | ★ 11.16 | N/A |
| Revenue | ★ $6,520,600,000.00 | N/A |
| Revenue This Year | $7.75 | $3.01 |
| Revenue Next Year | $5.28 | $5.80 |
| P/E Ratio | $27.88 | ★ $6.14 |
| Revenue Growth | ★ 6.37 | N/A |
| 52 Week Low | $248.63 | $43.51 |
| 52 Week High | $329.16 | $59.17 |
| Indicator | CME | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 31.35 |
| Support Level | $262.43 | N/A |
| Resistance Level | $329.16 | $48.97 |
| Average True Range (ATR) | 6.44 | 0.69 |
| MACD | -2.06 | -0.35 |
| Stochastic Oscillator | 40.71 | 2.66 |
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.